Osteogenesis Imperfecta (OI) is a genetic bone pathology with prenatal onset, characterised by brittle bones in response to abnormal collagen composition. There is presently no cure for OI. We previously showed that human first trimester fetal blood mesenchymal stem cells (hfMSC) transplanted into a murine OI model (oim mice) improved the phenotype. However, the clinical use of fetal MSC is constrained by their limited number and low availability. In contrast, human fetal chorionic stem cells (e-CSC) can be used without ethical restrictions and isolated in high numbers from the placenta during ongoing pregnancy. Here we show that intra-peritoneal injection of e-CSC in oim neonates reduced fractures, increased bone ductility and bone volume, increased the numbers of hypertrophic chondrocytes, and upregulated endogenous genes involved in endochondral and intramembranous ossification. Exogenous cells preferentially homed to long bone epiphyses, expressed osteoblast genes and produced collagen COL1A2. Together, our data suggests that exogenous cells decrease bone brittleness and bone volume by directly differentiating to osteoblasts and indirectly stimulating host chondrogenesis and osteogenesis. In conclusion, the placenta is a practical source of stem cells for the treatment of OI.
Introduction
Osteogenesis Imperfecta (OI), or brittle bone disease, is a debilitating inherited skeletal dysplasia with prenatal onset that affects 1 in 15,000-20,000 births. OI is characterised by short stature, osteopenia and multiple fractures. The severity of the disease ranges across the 11 known types depending on the causative mutation in collagen type I or genes involved in its biosynthesis, with type III being the most severe that survive the neonatal period [1, 2, 3, 4] . Existing treatments largely provide symptomatic relief, but there is currently no cure. The 'gold standard' bisphosphonates temporarily improve bone strength by inhibiting bone resorption, but do not improve growth or bone pain beyond a year [5] and do not reduce fracture incidence long term [6] .
Cell therapy in OI aims to prevent morbidity and deformity as well as mortality, by introducing healthy cells, early in development, with the aim that exogenous cells will home to bones and contribute to bone formation to decrease the severity of the disease [7] . Cell therapy for OI holds much promise, with most studies showing beneficial effects. In humans, whole bone marrow and bone marrow mesenchymal stem cells (MSC) have been transplanted in OI children with gains in body length and bone mineralization [8, 9] , whilst allogeneic fetal liver derived stem cells transplanted in utero led to apparent phenotypic improvement in an OI fetus, although confounded by concomitant bisphosphonate use [10] . In rodent OI models, transplantation of whole bone marrow/ bone marrow MSC led to increased collagen content [11] , improved bone strength, reduced perinatal lethality [12] and increased osteoblast differentiation [13, 14] . Marked therapeutic benefits were shown following transplantation of fetal MSC from human firsttrimester blood in a mouse model of human type III OI (oim) including improved bone plasticity and a two-third reduction in long bone fractures [15, 16] .
However, there are a number of hurdles to overcome before fetal stem cell therapy can be translated to the clinic. For example, it is essential to have a source of stem cells that have high therapeutic potential and are easily accessible for clinical use. Extra-embryonic fetal tissues, such as the placenta, are readily available either from termination of pregnancy or surplus tissue at routine prenatal diagnostic procedures [17, 18] , or at term delivery [19, 20, 21, 22] . Recently we have shown early gestation chorionic stem cells (e-CSC) isolated from human placental tissue accelerated tissue repair in dermal excision skin wounds and improved bone quality and plasticity in oim mice. This tissue repair capacity of e-CSC was greater than its late gestation counterparts in vivo, as was the osteogenic differentiation and cell expansion potential in vitro [23] . This may be due to the more primitive characteristics of e-CSC compared to term isolated CSC, which showed an intermediate phenotype between human embryonic stem cells (hESC) and MSC [23] .
We hypothesised that transplantation of stem cells derived from first trimester placenta would have therapeutic benefits in a mouse model of OI. Here, we show that exogenous e-CSC engrafted at sites of bone growth and repair in the oim model, differentiated to osteoblasts that produced COL1A2 and mediated changes in endogenous ossification genes, which resulted in reduced fractures and increased bone flexibility.
Materials and Methods

Cells
Collection of human early chorionic stem cells (e-CSC) was as previously described [23] from first trimester chorionic villous tissue sampled during pregnancy termination (9-10 weeks 6 secondary goat anti-murine IgM PE (Santa Cruz) [23] . Otherwise cells were analyzed by FACS calibur flow cytometry (Becton Dickinson) using hESC as positive and antibody-specific isotypes as negative controls.
Cell Differentiation
Cells were differentiated along the osteoblast lineage for 2 weeks in DMEM-LG supplemented with 10 mM β-glycerophosphate, 0.2 mM ascorbic acid and 10 -8 M dexamethasone, then fixed in 10% formalin and stained with von Kossa (2% silver nitrate) or 2% alizarin red. Cells were differentiated along the adipocyte lineage over 2 weeks in DMEM supplemented with 0.5 mM hydrocortisone, 0.5 mM isobutyl methylxanthine and 60 mM indomethacin, then fixed and stained with oil red O [23] . Cells were differentiated along the chondrocyte lineage over 2 weeks in DMEM-LG supplemented with 0.01µg/ml TGF-β3, 0.1µM dexamethasone, 0.17mM ascorbic acid, 1mM sodium pyruvate, 0.35mM L-proline, 1% ITSS, 50µg/ml Linoleic Acid (reagents from Sigma), then cells were fixed in and stained with alcian blue (2%). cells resuspended in 20 l of cold PBS) were injected intra-peritoneally (i.p.) into 3-4 day-old oim neonates (n=11 males, n=11 females) and mice were culled for analysis when they were 8 week old. We noted no variability between different isolated placenta specimens in terms of e-CSC phenotype (data not shown) and donor cells injected in oim mice were from a single donor.
Animals
Controls comprised age-matched non-transplanted oim and wild type mice.
Immunohistochemistry
Dissected tibias were decalcified in 10% EDTA pH7.4 and subsequently embedded in paraffin.
Four micron sections were cut, deparaffinised in xylene and rehydrated. Heat-induced epitope retrieval was performed in a steamer (Dako), followed by incubation with peroxidise block (Dako). The presence of donor cells in transplanted 8 week old oim mice was determined in 3 different regions of the non-fractured tibia (epiphysis, diaphysis and bone marrow) as well as in fracture callus. Donor cells were visualised using human-specific mouse monoclonal vimentin (Dako) primary antibody (Supplementary Table S1 ) and incubation with HRP-labelled antimouse polymer followed by DAB+ substrate-chromogen staining. Positive cells were counted in bone marrow (n=4 samples and n=4 sections for each). Staining specificity was verified using non-transplanted negative controls.
Detection of Collagen type X and Osteopontin (Supplementary Table S1 ) was performed on four micron sagittal sections of tibia from 8 week old mice, using HRP-labelled polymer followed by DAB+ substrate-chromogen staining.
Engraftment measured by quantitative real time PCR
Femurs of the same mice were dissected and separated into callus if present (n=8), epiphysis (n=6) and diaphysis (n=6). Liver (n=6) was also used. RNA was then extracted using TRIzol (Invitrogen) followed by cDNA synthesis with M-MLV reverse transcriptase (Promega). To calculate donor cell engraftment quantitative real time PCR (qRT-PCR) was performed using SYBR green dye (Applied Biosystem) and the ABI Prism 7700 Sequence Detection System with human specific and human-mouse non-specific β-actin primers (Supplementary Table S2 ).
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Human:mouse chimerism was estimated as the ratio of human β-actin to total human and mouse β-actin in the total cDNA sample to give the 2 -ΔCt value. Samples were considered positive with a human specific β-actin Ct above 36 at a threshold of 0.13ΔRn. Negative controls were nontransplanted oim [15] .
Quantitative real time RT-PCT
Osteoblast gene expression was performed by quantitative real time RT-PCR (QRT-PCR) using SYBR green dye (Qiagen) and the MJ-Opticon with human specific Osteopontin and Osteocalcin Table S2 ). Results with a Ct below 36 were normalised to human β-actin to give the 2 -ΔCt value. Expression in transplanted oim femurs (n=6) was compared to e-CSC (n=3) undifferentiated and grown in osteogenic permissive media for 2 weeks. Negative controls were non-transplanted oim [15] . Sox9 expression in ATDC5 cells was measured by QRT-PCR using the 2 -ΔCt method. Manufactured mouse-specific primers were from SABiosciences (Qiagen).
primers (Supplementary
Western blot
Collagen was extracted from ground bone over 72hrs at 4 o C in a lysis buffer of 6M guanidine HCl and 100mM Tris pH7.4 containing protease inhibitor cocktail. Proteins were precipitated with 10% TCA, re-suspended in RIPAE buffer (1xTBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% sodium azide; Sigma) containing PMSF (Sigma) and protease inhibitor cocktail, run on an 8% SDS-PAGE, transferred to nitrocellulose, blocked with milk and stained with a COL1A2 (129kDa) primary antibody (Abcam), then with an HRP-linked antirabbit IgG secondary antibody (GE healthcare), followed by enhanced chemiluminescence detection (Thermo scientific). The loading control used was β-ACTIN (43kDa) (Santa Cruz) [23] .
Detection of COL1A2 in transplanted oim bones was confirmed using wild type positive controls and specificity confirmed using non-transplanted oim negative controls (n=4 per group).
Mechanical testing
Three-point bending tests were performed as described [23] using a materials testing machine (5866 Instron) on 8 week old unfractured frozen and thawed femurs (n=22 transplanted oim, n=34 oim controls, n=14 wild type). Bones were bent mid-diaphysis to fracture on two supports 9 mm apart at a loading rate of 50 µm/s. Force deflection curves were analyzed (Matlab, MathWorks) to measure bending stiffness (slope of the linear elastic deformation; N/mm), load to fracture (maximum force sustained prior to fracture; N), maximum deflection (deflection at fracture in mm).
X-ray microradiography
Tibias from 8 week-old mice (n=19 transplanted, n=20 oim, n=11 wild type) were fixed in formalin for 24 hours and stored in 70% ethanol prior to removal of soft tissues. Digital X-ray images were obtained at a 10µm pixel resolution using a Faxitron MX20 variable kV point projection X-ray source and digital image system (Qados, Cross Technologies plc, Sandhurst, Berkshire, UK Bone mineralization densities were represented by a pseudocolour scheme representing 16 equal intervals [25] .
Counting of fractures
Fractures in both femurs, tibias and humeri were assessed at 8 weeks of age by determination of callus formation (n=120 transplanted, n=78 oim control). The number of mice with at least one long bone fracture and the fracture incidence (number of fractured bones/total bones assessed)
were calculated by two independent observers blinded to transplantation status. Deformities and callus formation in the caudal vertebrae (n=16 transplanted, n=10 oim control) were counted on digital X-ray images and the fracture rate was calculated as above. Fig.S1A ) and had normal morphology ( Supplementary Fig.S1B ),
while deformed vertebra had evidence of callus formation ( Supplementary Fig.S1C and Fig.S1D ) [16] .
Dynamic histomorphometry
Animals (n=7 transplanted, n=6 wild type, n=5 oim) were injected 10 days and 3 days before sacrifice with 20mg/kg of calcein (Sigma). Tibias were then fixed in formalin for 24hrs and transferred to 70% ethanol, before being dehydrated in acetone for 48hrs, infiltrated over 6-9 days at -20 o C and embedded in methylmethacrylate (MMA) [26] . Embedded samples were imaged on a Leica TCS SP5 confocal laser scanning microscope and analysed using ImageJ. Fluorescent images of calcein labels were taken 500µm and 1000µm below the proximal growth plate of the trabecular and endo-cortical regions respectively The amount of mineralizing surface per total bone surface (MS/BS;%), the daily mineral apposition rate (MAR;µm/day) and the bone formation rate (BFR;µm 3 /µm 2 /day) were calculated.
Static histomorphometry
MMA embedded samples were cut into 8μm sections and stained using the Leucognost AP kit (Merck), according to the manufacturer's instructions (n=6 transplanted, n=6 oim, n=5 wild type).
Sections were analysed on a light microscope using the Osteomeasure system (OsteoMetrics Inc).
Histomorphometric measurements of the secondary spongiosa were performed on stained sections 500µm from the end of the hypertrophic zone of the growth plate; % trabecular bone volume per total tissue volume (BV/TV) was quantified. For growth plate analysis dissected tibia were decalcified, paraffin embedded and 5µm sections were cut and stained with alcian blue 8GX (2%), Weigert's haematoxylin and van Gieson, mounted and growth plate morphology analysed using ImageJ (n=14 transplanted oim, n=5 oim, n=5 wild type).
Osteogenesis PCR array
Total RNA was extracted from femoral epiphysis of 8 week-old mice using TRIzol (Invitrogen), followed by RNA clean up (RNeasy Qiagen) and cDNA synthesis using an RT 2 First Strand Kit (Qiagen). Gene expression was investigated using an RT 2 Profiler mouse osteogenesis PCR array (Qiagen) and analysed according to the manufacturer's instructions (n=3 mice per group). To verify results, quantitative real time PCR was performed using RT 2 qPCR Master Mix and primers (Supplementary Table S2 ) and analysed with MJ-opticon (Biorad). Data were normalised to 2 housekeeping genes (β-Actin and Hsp90ab1) and the 2 -ΔCt of each sample calculated (n=8 transplanted oim, n=5 oim controls).
Protein measurement
Cells were cultured either in D10 medium (non-primed) or in co-culture without cell contact with ATDC5 cells (primed with ATDC5) or in the presence of blood serum from oim or wild type mice (primed with oim or WT serum) for 7 days. The mouse cell line ATCD5 is chondrogenic and goes through a sequential process analogy to chondrocyte differentiation, constituting an excellent in vitro model cell line for analysing skeletal development and studying the factors involved in chondrogenesis [27] . The presence of protein was measured in the medium using Mini ELISA development kits (Peprotech, London, UK) for the detection of human-specific basic fibroblast growth factor (bFGF), platelet-derived growth factor-BB (PDGF-BB) and connective tissue growth factor (CTGF), following the manufacturer's protocol. Briefly, ELISA microplates (Corning) were incubated overnight with capture antibody, washed with 0.05% Tween-20 in PBS (Sigma), incubated with standards or samples for 2 hours, washed and incubated with detection antibody for 2 hours, followed by washing and incubation with Avidin-HRP conjugate for 30
minutes. Finally, substrate was added to the wells and colour development was monitored at 405nm with wavelength correction set at 650nm. For the detection of human factor IX in blood serum of transplanted oim mice, a kit containing microplates pre-coated with antibody was used (Abcam), using the protocol recommended by the manufacturer. Detection was carried out at 450nm.
Statistical analysis
Data were expressed as mean ± s.e.m (standard error). Normally distributed data were analyzed by unpaired two-tailed Student's t-test or one-way ANOVA followed by a Tukey's multiple comparison post-hoc test. P < 0.05 was considered significant. Two-tailed 2x2 Fisher exact was used for categorical comparisons. Cumulative frequency distributions of bone mineral densities were compared using the Kolomogorov-Smirnov test. Chi-squared with Yates correction and to one degree of freedom was used to compare fracture incidence.
Results
Characterisation of e-CSC
The e-CSC transplanted in neonatal oim have a pre-pluripotent phenotype as previously described [23] , showing some characteristics of both MSC [28] and human embryonic stem cells (hESC) [29, 30] . MSC traits were demonstrated by positive expression of adhesion molecules CD29 and CD44, and the MSC-associated markers CD73, CD90 and CD105, and absent expression of the endothelial or hematopoietic markers CD14, CD34 and CD45, while presenting low levels of intracellular HLA I and no expression of HLA II, similar to fetal liver MSC [31] (Fig.1A) . A sub fraction of cells expressed key hESC markers required for the maintenance of pluripotency;
OCT4A, SOX2, TRA-1-60 and SSEA4 ( 
Bones of transplanted mice are less liable to fracture
Eight weeks after e-CSC were transplanted, 11/20 oim mice (55%) had no long bone (femur, tibia and humerus) fractures, whereas all non-transplanted oim controls (100%; n = 13) had at least one or more long bone fracture ( Fig.2A) . The fracture incidence in long bones, calculated as the number of fractured tibia, femur and humeri over the total number of these bones, was reduced from 29.5% (23/78 total bones) in non-transplanted oim to 10.0% (12/120 total bones) in e-CSC transplanted oim. This corresponds to a 66% decrease in fracture rate (X 2 =21, P<0.001) (Fig.2B) .
We next counted the number of caudal vertebra fractures on digital X-Ray, with a fracture classified as any vertebra having a callus or evidence of bone remodelling (see Supplementary   Fig.1 and Methods section for classification of normal and fractured vertebra by microCT).
Compared to non-transplanted oim (n=10), which showed an average 46.6% ± 4.2 incidence of fractured vertebra per mouse, transplanted mice (n=16) had 29.2% fewer vertebral fractures at an average incidence of 33.0% ± 2.2 per mouse (X 2 =33.8, P<0.001) (Fig.2C) . The reduction of vertebral fractures from the non-transplanted control group was widespread, with overall numbers of vertebrae with callus reduced across the majority of vertebral positions (Fig.2D) . Most fractures were found in proximal caudal vertebrae, where force is exerted when rearing up to feed.
Transplanted mice have bones with reduced stiffness and increased ductility
We previously reported 3-point bending data from femurs of oim mice transplanted with either early (e-CSC) or late (l-CSC) gestation CSC [23] . Mice transplanted with e-CSC had greater plasticity and overall bone quality than l-CSC transplanted or control oim due to an increased post-yield strain. Here we further analysed the 3-point bending load-displacement curves to show that e-CSC transplanted oim were also more ductile due to a reduction in stiffness in the pre-yield region and an increase in maximum deflection before fracture (Fig.2E ). Bone stiffness of e-CSC transplanted oim was reduced by an average of 16% compared to non-transplanted oim femurs (29.7 N/mm ± 2.1 s.e.m vs. 35.3 N/mm ± 1.7 s.e.m respectively, P<0.05) (Fig.2F) , while the maximum deflection was increased in transplanted compared to control oim by an average of 24% (0.26 mm ± 0.02 s.e.m vs. 0.21 mm ± 0.01, P<0.05 respectively) (Fig.2G) . However, the maximal load sustained by transplanted and non-transplanted oim femurs prior to fracture was similar (4.5 N ± 0.3 vs. 4.8 N ± 0.3) (Fig.2H) . In contrast, wild type compared to oim bones were stiffer (73.6 N/mm ± 2.0, P<0.001) (Fig.2F) , with greater maximum deflection (0.88 mm ± 0.07, P<0.001) (Fig.2G ) and sustained higher loads before fracture (14.0 N ± 0.5, P<0.001) (Fig.2H ).
Thus the material properties of bones from transplanted oim were not intermediate between the
properties of wild type and oim bone. Instead bones from transplanted oim were of similar strength to non-transplanted oim, but displayed greater plasticity and ductility which may explain their reduced fracture susceptibility.
Transplanted e-CSC preferentially home to oim epiphysis
We first performed an ELISA for human factor IX in blood serum of transplanted mice. Results
showed absence of mouse anti-human antibodies, indicating an absence of immune reaction of the neonatal murine immune system (data not shown).
Donor cells were visualised by immunohistochemistry in 8 week-old e-CSC transplanted oim using a rabbit monoclonal to human vimentin. Staining was localized at the epiphysis, diaphysis, and sites of fracture callus, with some cells present in the primary spongiosa below the growth plate (Fig.3A) . Quantitative real time PCR (qRT-PCR) showed that donor cell engraftment in transplanted oim was highest in the epiphysis, the site of active bone formation. This was 7.1 fold (P<0.001) higher than in the non-fractured diaphysis where bone formation is less active, and 11.7 fold (P<0.01) higher than engraftment in the liver (Fig.3B ). Donor cells also preferentially homed to sites of bone repair, where engraftment was 4 fold (P<0.01) higher than engraftment in the liver. Engraftment in fractured and non-fractured diaphysis were not significantly different, but interestingly more mice were positive for human cDNA in the diaphysis if a fracture callus was present; 90% compared to 60%. Engraftment within the femoral epiphysis was inversely correlated (R 2 =0.64, y= -0.96x + 41.43, P<0.01 deviation from zero) with bone stiffness, indicating that bone flexibility increases with increasing numbers of donor cells (Fig.3C ).
Exogenous cells undergo osteogenic differentiation in vivo
To determine if transplanted cells underwent osteogenic differentiation in vivo expression using qRT-PCR was determined for human specific Osteopontin (OP); a major interfacial noncollagenous extracellular matrix proteins found in bone and secreted by osteoblasts [32] and also for Osteocalcin (OC); an osteoblast specific gene [33] with an important role in osteoblast differentiation [34] . Results showed expression of human OP and OC in the transplanted mouse bones (0.38 2 -ΔCt ± 0.08 s.e.m and 0.85 2 -ΔCt ± 0.18, respectively), which was greater than expression in e-CSC after growth in osteogenic permissive media for 2 weeks (0.05 2 -ΔCt ± 0.03, P<0.05 and 0.06 2 -ΔCt ± 0.04, P<0.05, respectively) and greater than the low/null basal expression level of the undifferentiated cells (Fig.3D ). Western blot analysis showed the COL1A2 protein, missing in non-transplanted oim [35] , was present in the femoral bones of oim transplanted with e-CSC (Fig.3E) , which demonstrates osteogenic differentiation of donor cells to functional osteoblasts.
Transplantation of e-CSC did not affect bone length or cortical bone formation
Tibial length was unaffected by transplantation being similar in transplanted oim compared to control oim (15.1mm ± 0.1 and 15.2mm ± 0.1 respectively), with both being shorter than wild type tibia (17.0mm ± 0.1, P<0.001) (Fig.4A) . The diameter of the tibia at the mid-diaphysis was also similar in transplanted and control oim (1.01 mm ± 0.01 and 1.05mm respectively) but less than in wild types (1.28 mm ± 0.02, P<0.001) (Fig.4B) . The cortical bone thickness was decreased in oim compared to wild type (17.9% ± 0.5 and 20.4% ± 0.3, P<0.001 respectively), and was similar in untransplanted and transplanted oim mice (17.9% ± 0.5 vs 17.2% ± 0.5) (Fig.4C ). Fig.S2A ), because there was no difference in mineralizing surface (92% ± 2 vs. 90% ± 2, respectively) (Supplementary Fig.S2B ). The MAR and mineralizing surface, however, did not differ between transplanted and non-transplanted oim mice ( Fig.4D and Supplementary Fig.S2A and Fig.S2B ).
Transplantation increases trabecular bone volume, but not BMC
The total bone mineral content (BMC) of combined trabecular and cortical bone compartments did not differ between transplanted and non-transplanted oim mice, both of which had markedly reduced BMC compared to wild-type (P<0.001) ( Fig.4E and Supplementary Fig.S3 ).
Trabecular bone volume per total tissue volume (BV/TV), however, was increased in transplanted compared to non-transplanted oim mice (4.1% BV/TV ± 0.6 vs. 2.0% ± 0.4 respectively, P<0.05), but remained lower than in wild type mice (11.9% ± 0.9) (Fig.4F) Fig.S4A ). MS/BS did not differ between transplanted oim, non-transplanted oim and wild type mice (Supplementary Fig.S4B ).
Transplantation reduces endogenous Smad3 expression and increases expression of genes activated during endochondral ossification.
The mouse osteogenesis array (SABiosciences) was used to analyse changes in endogenous gene expression within the femoral epiphysis, and showed a global increase in expression of cartilage gene groups in e-CSC transplanted mice compared to non-transplanted oim controls (Fig.5A ). 
Up-regulation of genes activated during intramembraneous ossification in transplanted mice is associated with increased endogenous expression of Runx2
The PCR array also identified genes involved in intramembraneous ossification that were upregulated in transplanted mice compared to oim controls. There was a 2.8 fold (P<0.05) increase in Phex and a 2.9 fold (P<0.05) increase in Dmp1, genes that are co-expressed by osteoblasts and osteocytes and which regulate osteoblast maturation as well as bone mineralization via FGFR signalling pathways [48, 49] . Also up-regulated in transplanted oim was Bgn, which has a role in osteoblast differentiation and matrix mineralisation [50] , and Serpinh1, which acts as a molecular chaperone in collagen biosynthesis [51] (2.6 fold, P<0.05, and 3.5 fold, P<0.05 respectively).
These findings correlated with higher expression of extracellular matrix proteins in transplanted mice, including a 3.2 fold increase in Col1α1 (P<0.01), involved in fibril formation of the abundant collagen type I [1, 52] (Fig.5A) .
Array results were confirmed by qRT-PCR and showed Runx2 expression, essential for osteoblast differentiation [53, 54, 55] , was also increased in transplanted mice compared to non-transplanted oim (2.1 x10 -2 2 -ΔCt ± 0.2 x10 -2 vs. 1.3 x10 -2 2 -ΔCt ± 0.3 x10 -2 respectively, P<0.05) (Fig.5C ).
However, expression of the downstream transcription factor osterix, also required for osteoblast differentiation [56, 57] was similar in both e-CSC transplanted oim and non-transplanted controls (3.7 x10 -2 2 -ΔCt ± 0.5 x10 -2 vs. 3.3 x10 -2 2 -ΔCt ± 0.7 x10 -2 respectively). In contrast Igf1, which regulates both osteoblasts [58] and osteoclastogenesis via induction of RANK-L synthesis [59, 60] and stimulates linear growth [61] was up-regulated in transplanted mice (0. Fig.S5A ). Likewise expression of the co-activators Dmp1
and Phex were strongly correlated (R 2 =0.91, P<0.001) (Supplementary Fig.S5B ), as was expression of the ECM genes Col1α1 and Bgn (R 2 =0.93, P<0.001) (Supplementary Fig.S5C ).
Protein evaluation was performed in situ by immunohistochemistry, confirming increased expression of cartilage hypertrophic marker Collagen Type X and increased expression of the osteoblastic marker osteopontin in mice treated with e-CSC compared to non-treated mice ( Fig.5D and Fig.5E )
Growth plate height is increased in e-CSC transplanted oim
Analysis of growth plate height confirmed previous findings [15] that oim have larger growth plates than wild type mice (153μm ± 7 vs. 137μm ± 9 respectively, P<0.05). Interestingly e-CSC transplanted oim had a substantially wider growth plate (184μm ± 6) than oim controls (P<0.05),
primarily the result of a larger hypertrophic zone (84μm ± 4 for e-CSC transplanted oim vs. 60μm ± 7 for oim controls, P<0.01) (Fig.6A and Fig.6B ). When the relative proportions of the growth plate zones were calculated, the hypertrophic zone formed a larger proportion of the total growth plate in the transplanted mice than in non-transplanted oim mice (46.4% ± 1.1 vs. 39.5% ± 3.2 respectively, P<0.05), in which the hypertrophic zone was similar to wild type (41.7% ±1.2) (Fig.6C ). This finding was consistent with gene expression studies demonstrating that transplanted oim had a 10:1 ratio of expression of the late hypertrophic chondrocyte marker Col10α1 in the epiphysis compared to expression of the proliferating chondrocyte marker Col2α1, whereas in non-transplanted oim the ratio was 4:1 (P<0.05).
There was a positive correlation (R 2 =0.75, y=20.13x -0.84, P<0.01) between endogenous
Col10α1 expression and the size of the hypertrophic zone of chondrocytes in the growth plate (Fig.6D) . Whilst Runx2 expression was also correlated with the expression of Col10α1 (R 2 =0.76, y=65.56x -0.41, P<0.001) (Fig.6E ) and may therefore be involved in mediating the larger hypertrophic zone in the growth plate. We also show a strong correlation between Igf1 and Bgn expression (R 2 =0.89, y=8.64x -0.15, P<0.001), highlighting the importance of Igf1 in regulating genes activated during intramembraneous ossification (Fig.6F) .
We next wanted to provide mechanistic clues as to how e-CSC transplantation induces upregulation of endogenous genes involved in skeletogenesis. We hypothesized that donor cells produce growth factors that stimulate maturation of endogenous chondrocyte progenitors. To test this hypothesis, we cultured e-CSC with the chondrogenic cell line ATDC5 to investigate whether e-CSC would produce factors that stimulate chondrogenic differentiation and maturation of ATDC5 cells. Although expression of the chondrogenic marker sox9 was higher in ATDC5 cells cultured in chondrogenic differentiated medium compared to levels found in non-induced cells, sox9 levels were not up-regulated when ATDC5 cells were co-cultured without cell contact with e-CSC, indicating that e-CSC do not produce soluble factors that induce chondrocyte maturation in vitro (Fig.6G) . Interestingly, although ELISA analysis showed e-CSC did not produce bFGF, CTGF and PDGF-BB when cultured in D10 medium, they produced CTGF, but not bFGF or PDGF-BB, when co-cultured with ATDC5 (Fig.6H ). When primed with oim or wild type seri, e-CSC produced both bFGF and CTGF, but not PDGF-BB, indicating the cells might respond to in vivo signals present in blood serum (Fig.6H) .
Discussion
This study demonstrates that fetal stem cells derived from human first trimester chorionic placental tissue (e-CSC), have therapeutic benefits in the OI mouse model (oim) as evidenced by a two-third decrease in long bone fracture incidence and decreased bone brittleness compared to non-transplanted controls. These results are in line with our previous studies [15, 16, 62] . Fracture reduction in e-CSC transplanted mice was attributed to an increase in bone plasticity, as previously demonstrated [23] , as well as greater bone ductility. Changes to the bone mechanical properties of transplanted oim were most likely mediated by the exogenous cells since higher engraftment levels in bones correlated with decreased bone stiffness. This is in agreement with recent work from our group showing that up regulation of CXCR4 in transplanted fetal blood MSC increased cell homing to sites of injury via the CXCR4-SDF1 pathway [62, 63] , which subsequently increased donor cell engraftment as well as bone plasticity and bone quality [62] .
Transplanted e-CSC homed to areas of bone growth and fracture repair and expressed osteoblast differentiation genes Osteopontin and Osteocalcin as well as the COL1A2 protein, indicating their differentiation to functional osteoblasts. These findings are in agreement with previous studies in the oim model that demonstrated the direct differentiation of transplanted cells to osteoblasts [13, 14, 15, 16] and subsequent improvements in disease pathology. In addition, we used the detection of human factor IX as an immunoassay to detect the presence of mouse antihuman antibodies in the serum of mice transplanted with human cells and we were able to show the absence of immune reaction against allogeneic cells.
The trabecular bone volume (BV/TV) of oim is lower than wild type mice due to the impaired osteoblast differentiation of oim [64, 65] , which results in a high numbers of preosteoblasts that support greater osteoclast bone resorption [64] . Oim mice transplanted with e-CSC had a higher BV/TV than non-transplanted oim, despite bone formation rate remaining the same, which could be due to differentiation of exogenous cells to normal osteoblasts that better regulate bone remodelling. Increased BV/TV may also result from an indirect effect of the transplanted cells on osteoblast differentiation as demonstrated by the upregulated expression of endogenous genes in transplanted oim that were associated with osteoblast differentiation, including Dmp1, Phex and
Bgn [48, 49, 50] . Others have also shown an effect of transplantation on endogenous osteoblast activity, for example transplantation of osteogenic differentiated MSC in SCID mice resulted in increased bone being produced by host cells [66] , and endogenous osteoblast numbers were increased after transplantation of term placental stem cells in a SCID-rab mouse model of medullary myeloma-associated bone loss [67] . We also showed upregulation in transplanted oim of endogenous chondrogenesis genes including chondrogenesis regulator Sox9 [38] and Runx2, implicated in chondrocyte maturation through Col10α1 transactivation [68] . Whilst expression of chondrocyte maturation inhibitor Smad3 [46] was downregulated in transplanted mice. These changes were associated with a larger zone of hypertrophic chondrocytes within the growth plate, and indicate transplantation may have increased endogenous endochondral ossification.
The larger growth plate of e-CSC transplanted oim compared to oim controls is in contrast to previous data with hfMSC that instead showed normalisation of growth plate height in prenatally-
transplanted oim compared to controls [15] . 
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BMC measured at the whole bone scale did not increase in oim after transplantation of e-CSC, despite changes in bone mechanical properties. Others have shown the importance of the collagen matrix organization on bone mechanical properties [70, 71] and recently we have shown using nanoindentation that compared to wild type mice, oim have greater mineralization of a poorly organized matrix [72] . Therefore exogenous cells may have affected the bone mineralization or improved organization of bone matrix collagen fibres in the oim bones at the microscopic matrix scale, potentially in response to production of normal COL1A2.
To test the hypothesis that e-CSC produce growth factors which promote endogenous chondrocyte progenitor maturation and differentiation, we co-cultured e-CSC with ATDC5 in vitro. Interestingly, co-culture with ATDC5 cells induce e-CSC to produce connective tissue growth factor CTGF, which is known to induce chondrocytic proliferation, maturation and hypertrophy in vitro [73] . Interestingly, when primed with blood serum, e-CSC produced both CTGF and bFGF. CTGF is also known for stimulating proliferation and differentiation of cultured osteoblastic cells, and bFGF, which stimulates proliferation in the perichondrium [72] .
Together, these results suggest e-CSC respond to in vivo signals to produce CTGF and bFGF, which may stimulate endogenous osteogenesis and chondrogenesis.
In summary, our study demonstrates that fetal stem cells derived from first trimester chorionic tissue have the potential to treat osteogenesis imperfecta. Loading control is GAPDH. 
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